CHADS2 score: clinical prediction rule for assessing the
risk of stroke in patients with non-rheumatic atrial fibrillation. The
result can be used to determine whether or not treatment is required with
anticoagulation therapy or antiplatelet therapy. A high CHADS2
score corresponds to a greater risk of stroke, while a low CHADS2
score corresponds to a lower risk of stroke. The CHADS2 score was
validated by a study of nonrheumatic atrial fibrillation patients aged 65 to 95
who were not prescribed the anticoagulant warfarin.
References:
[1 ]
Gage BF, van Walraven C, Pearce L, et al. (2004). "Selecting patients with
atrial fibrillation for anticoagulation: stroke risk stratification in patients
taking aspirin". Circulation 110 (16): 2287–92.
[2 ]
Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ (2001).
"Validation of clinical classification schemes for predicting stroke: results
from the National Registry of Atrial Fibrillation". JAMA 285 (22): 2864–70.
[3 ]
Go AS, Hylek EM, Chang Y, et al.
Anticoagulation Therapy for Stroke Prevention in Atrial Fibrillation: How Well
Do Randomized Trials Translate Into Clinical Practice? JAMA.
2003;290(20):2685-2692
|